One-year Clinical Outcome of Topical Bromfenac in Central Serous Chorioretinopathy
10.3341/jkos.2024.65.7.435
- Author:
Mi Sun KWON
1
;
Yu Min KIM
;
Jin Young KIM
;
Jae Rock DO
;
Yong Koo KANG
;
Dong Ho PARK
Author Information
1. Department of Ophthalmology, School of Medicine, Kyungpook National University, Daegu, Korea
- Publication Type:Original Article
- From:Journal of the Korean Ophthalmological Society
2024;65(7):435-441
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Purpose:To evaluate the efficacy of topical bromfenac in treating central serous chorioretinopathy (CSC) over a 1-year period.
Methods:A retrospective analysis was conducted on 57 patients (57 eyes) with CSC followed for > 1 year. Patients were divided into two groups: those treated with bromfenac eye drops twice daily (29 eyes) and a control group (28 eyes). Best-corrected visual acuity (BCVA), central macular thickness (CMT), and subretinal fluid (SRF) height were measured and compared between the two groups as was the proportion of chronic cases.
Results:Significant improvements in CMT and SRF height were noted in both groups over the follow-up period. The bromfenac group demonstrated significantly lower CMT at 6, 9, and 12 months (p = 0.045, 0.042, and 0.023, respectively) and lower SRF height (p = 0.037, 0.048, and 0.046, respectively) compared to the control group. The proportion of chronic cases was significantly lower in the bromfenac group (17.2%) compared to the control group (42.9%, p = 0.035).
Conclusions:Topical bromfenac reduced the rate of progression to chronic CSC and showed significant anatomical improvements after 6 months, suggesting its potential as an effective treatment option.
